Browsing Tag
David Bryant
2 posts
Avacta Therapeutics (AIM: AVCT) names Richard Hughes chairman as Shaun Chilton steps back
Avacta hands the chair to dealmaker Richard Hughes and adds a biotech deputy, a boardroom rebuild aimed squarely at pharma partnering. Read more.
Avacta FY25 puts AVCT on a clock: £16.9m cash, two Phase 1 reads, one shot
Avacta Group posts FY25 results with two clinical assets in trial, £16.9m cash, and AVA6103 data due in H2 2026 as AVCT trades near 52-week high.